Oral GLP-1s explained: what you need to know about the new weight-management tablet

July 1, 2026

A clinical perspective from Dr Gaurav Sabharwal, Founder of One5 Health

For the last few years, the conversation around medical weight management has been dominated by once-weekly injections. That conversation is now shifting, because the same class of medication has arrived as a daily tablet. If you have seen headlines about a "weight-loss pill" and wondered what is real, what is hype, and whether it might be right for you, here is a clear and honest guide from a doctor's point of view.

First, what is a GLP-1 medicine?

GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally releases after you eat. It acts on the parts of the brain that regulate appetite and fullness. GLP-1 medicines work by mimicking that hormone. They reduce appetite, slow how quickly the stomach empties, and help people eat less without feeling constantly hungry. Used alongside genuine changes to diet, activity and lifestyle, they can support meaningful and sustained weight loss.

Until recently, the GLP-1 medicines licensed for weight management in the UK were only available as injections. The newer development is an oral GLP-1: the same class of medicine, taken as a tablet.

What has actually changed

On 11 June 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the UK's first GLP-1 tablet licensed specifically for weight management. It is a daily oral form of semaglutide, the same active ingredient found in the well-known weekly injection sold under the brand name Wegovy. For people who are uncomfortable with needles, or who simply prefer a tablet, this is a genuinely new option.

It is worth being precise here, because there is real confusion. A lower-dose oral semaglutide has existed for several years under the brand name Rybelsus, but that product is licensed for type 2 diabetes at doses up to 14mg, not for weight management. The newly approved tablet is a higher-dose, weight-management medicine reaching up to 25mg. They are not the same product, and the doses are not directly comparable.

One practical point for existing patients: the MHRA has indicated that people already established on the 2.4mg weekly semaglutide injection can, after clinical assessment, transition directly to the 25mg daily tablet rather than restarting the dose ladder from the beginning.

How does the tablet compare to the injection?

This is the question everyone asks, and the honest answer is nuanced.

The UK approval is based on the OASIS 4 trial. In that study, the licensed 25mg tablet produced an average weight loss of around 14% of body weight over 64 weeks, which is roughly fifteen months, compared with around 2% on placebo, both alongside diet and activity changes. That is broadly comparable to the original standard 2.4mg dose of the weekly injection. The newest, highest-dose injectables, including higher-dose semaglutide and tirzepatide, have shown somewhat greater average weight loss in their own trials.

So the tablet is not simply "better" or "worse". It is a different balance. Its real advantage is convenience and being needle-free. The trade-off is that the most powerful average results still come from injections, and the tablet has to be taken in a very particular way to work properly.

The part people miss: how you take it matters

An oral GLP-1 is not just an easier version of the injection. Semaglutide is poorly absorbed from the gut, so for the tablet to work it has to be taken exactly as directed:

First thing in the morning, on an empty stomach, after fasting for at least eight hours
Swallowed whole, with no more than a small sip of plain water, never crushed, chewed or split
Followed by a wait of at least thirty minutes before eating, drinking anything else, or taking other tablets

Get this routine wrong and the medicine is not absorbed well, which means it simply will not work as it should. Because semaglutide also slows stomach emptying, it can affect how other oral medicines are absorbed, which is something we review on a case-by-case basis. For some people this daily discipline is easy. For others, particularly those whose wake-up time varies or who take other tablets first thing, it is the deciding factor. It is an important thing to think through honestly before starting, and a weekly injection may suit some people better for exactly this reason.

The tablet is also escalated gradually, starting at 1.5mg daily and stepping up through 4mg, 9mg and 25mg, with at least one month at each level. This slow titration is deliberate, and it is one of the main reasons early side effects tend to settle.

Is it right for everyone? No, and that matters

These are prescription-only medicines for good reason. They are intended for adults who meet specific medical criteria: in line with the UK licence, generally a body mass index of 30 or above, or a BMI of 27 or above alongside a weight-related health condition. They are not suitable for everyone.

A few things a responsible clinician will always cover:

They are not for use in pregnancy, when breastfeeding, or when trying to conceive, and anyone who could become pregnant should discuss contraception before starting.
Side effects are common, especially early on. Most are digestive, usually nausea, and tend to settle as the dose is increased gradually.
Rare but serious risks exist, such as inflammation of the pancreas. Knowing the warning signs and when to seek urgent help is part of safe treatment.
Certain personal and family medical histories make these medicines unsuitable, which is exactly what a proper assessment is designed to identify.

This is why these medicines should always be prescribed and monitored by a clinician who knows your history, not bought from an unregulated website.

"Is there an oral Mounjaro?"

Another common question. Mounjaro (tirzepatide) is currently injection-only, and there is no licensed tablet version of it in the UK. A separate oral medicine, orforglipron, is in development from a different manufacturer and may arrive later, with a UK decision expected in due course. It is a different drug that works on a single hormone pathway rather than two, and early trial results suggest more modest average weight loss in exchange for a more flexible routine, with no fasting window. For now, the oral option licensed for weight management in the UK is semaglutide.

A note on NHS access

It is worth being clear about availability. The MHRA approval allows the tablet to be prescribed privately. It is not currently available on the NHS, which is pending an assessment by the National Institute for Health and Care Excellence (NICE). Approval and access are two separate steps, and at launch this will be a private, clinician-led route.

The One5 view: medication is one piece, not the whole picture

At One5 Health, our philosophy is preventative and whole-person, with one patient at the centre of the five pillars of health. Medication, where appropriate, can be a powerful tool, but it works best as part of a properly supported plan: the right clinical assessment first, then nutrition, movement and regular medical review alongside it. That is the difference between a doctor-led programme and simply being sent a prescription.

It is also why sourcing matters. Weight-management medicines bought from unregulated online sellers can be counterfeit and unsafe. Anything you take should come through a regulated, clinician-led route.

A note from our clinical team As doctors, we welcome more options for our patients, and a needle-free choice is a real step forward for people who have been put off by injections. But a tablet does not change the fundamentals. The medicine is one part of a plan, not the plan itself. The questions we care about are whether treatment is clinically appropriate for you, whether it is safe given your history, and how we support the lifestyle changes that make any result last. That assessment is where good care starts.

Thinking about your options?

If you are weighing up whether medical weight management, in any form, is right for you, the best first step is not choosing a medicine. It is understanding your own health and getting proper clinical guidance.

The simplest place to start is our quick online eligibility form. It takes just a few minutes, and a One5 Health doctor reviews every submission. If you are eligible, you will be invited to book an initial consultation: a thorough first appointment that includes a comprehensive blood panel, body composition analysis and full clinical oversight, so any plan is built around your individual health rather than a one-size-fits-all approach.

Available in person in London or virtually across the UK.

Complete the eligibility form →

This article is for general information and is not medical advice. GLP-1 medicines are prescription-only and are not suitable for everyone, and individual results vary. Always speak to a qualified clinician about your own circumstances before starting any treatment.